Retinal and Renal Vascular Permeability Changes Caused by Stem Cell Stimulation in Alloxan-induced Diabetic Rats, Measured by Extravasation of Fluorescein

被引:1
作者
Doczi-Keresztesi, Z. [1 ]
Jung, J. [2 ]
Kiss, I. [3 ]
Mezei, T. [2 ]
Szabo, L. [4 ]
Ember, I. [3 ]
机构
[1] Univ Med & Pharm, Dept Pharmacol, Targu Mures 540139, Romania
[2] Univ Med & Pharm, Dept Pathol, Targu Mures 540139, Romania
[3] Univ Pecs, Dept Publ Hlth, Pecs, Hungary
[4] Crystal Inst KFT, Eger, Hungary
来源
IN VIVO | 2012年 / 26卷 / 03期
关键词
Diabetic retinopathy; nephropathy; stem cell stimulation; alloxan; experimental diabetes; FITC-BSA; Olimpiq StemxCell; ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW-CELLS; BARRIER BREAKDOWN; PROGENITOR CELLS; RETINOPATHY; DISEASES; MOUSE; COMPLICATIONS; LOCALIZATION; MOBILIZATION;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aim: To determine whether treatment with the stem cell stimulator Olimpiq (R) StemxCell prevents increase of retinal and renal vascular permeability in alloxan-induced diabetic rats. Materials and Methods: Two groups of Wistar rats were made diabetic by single intraperitoneal injection of Alloxan. The third, the control group, received vehicle alone. One diabetic group received Olimpiq (R) StemxCell treatment for 4 weeks. The permeability of the blood retinal barrier (BRB) and renal vessels were measured by the extravasation of fluorescein labeled bovine serum albumin. Results: Six weeks subsequently to Alloxan injection, significantly elevated the tissue fluorescence, the renal vascular leakage and BRB breakdown was demonstrated in the diabetic group, compared to the nondiabetic group. Olimpiq (R) StemxCell treatment significantly reduced the BRB breakdown, tissue fluorescence, and vascular leakage. Conclusion: Olimpiq (R) StemxCell would be a useful choice of treatment for complications associated with increased vascular permeability of diabetes, such as retinopathy or nephropathy.
引用
收藏
页码:427 / 435
页数:9
相关论文
共 42 条
[41]   Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030 [J].
Wild, S ;
Roglic, G ;
Green, A ;
Sicree, R ;
King, H .
DIABETES CARE, 2004, 27 (05) :1047-1053
[42]  
Zulewski H, 2008, PANMINERVA MED, V50, P73